This was also the case in the KEYNOTE 061 trial looking at the efficacy of pembrolizumab vs. chemotherapy as second-line therapy, including patients with advanced GOJ cancers who showed no improvement in overall survival with the use of this PD-1 inhibitor compared to standard chemotherapy [58]. This evidence concerns the gene PDCD1 and cancer.